MedTrace Logo

A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

NCT00945672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.

Conditions

Interventions

BIOLOGICAL

PF-04360365 10 mg/kg

10 mg/kg every 90 days (5 total doses)

BIOLOGICAL

PF-04360365 7.5 mg/kg

10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)

DRUG

placebo

placebo administered every 90 days or monthly to match experimental treatment arms.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-06
Primary Completion
2011-06-01
Completion
2011-06-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945672 on ClinicalTrials.gov